Europe Preclinical Imaging Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2024 –2030 |
 Taille du marché (année de référence) |
|
 Taille du marché (année de prévision) |
Dollars américains 682,607.83 |
 TCAC |
% |
| Principaux acteurs du marché |
Marché européen de l'imagerie préclinique, par produit (systèmes et services), réactif (réactifs d'imagerie optique préclinique, réactifs d'imagerie nucléaire préclinique, agents de contraste IRM préclinique, agents de contraste échographiques précliniques et agents de contraste CT préclinique), application (recherche et développement, découverte de médicaments, biodistribution, détection de cellules cancéreuses, biomarqueurs et autres), utilisateur final (organisme de recherche sous contrat, sociétés pharmaceutiques et biotechnologiques, instituts de recherche universitaires et gouvernementaux, centre de diagnostic et autres) - Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et taille du marché de l'imagerie préclinique en Europe
Le marché est l'industrie impliquée dans la fourniture de solutions et de technologies d'imagerie pour mener des recherches et des expérimentations sur des animaux (généralement des rongeurs) au stade préclinique du développement de médicaments et de la recherche médicale. Ces techniques d'imagerie sont essentielles pour évaluer la sécurité et l'efficacité des candidats médicaments potentiels et des traitements médicaux avant qu'ils ne passent aux essais cliniques impliquant des sujets humains. L'imagerie préclinique permet aux chercheurs et aux sociétés pharmaceutiques d'évaluer les effets des candidats médicaments sur les organismes vivants avant de passer aux essais sur l'homme. Cela permet d'identifier les problèmes potentiels, d'optimiser les schémas posologiques et de réduire le risque d'effets indésirables aux stades ultérieurs.
Data Bridge Market Research analyse que le marché européen de l'imagerie préclinique devrait atteindre la valeur de 682 607,83 milliers USD d'ici 2030, à un TCAC de 5,9 % au cours de la période de prévision.
Ce rapport de marché couvre également en profondeur l’analyse des prix et les avancées technologiques.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable de 2015 à 2020) |
|
Unités quantitatives |
Chiffre d'affaires en milliers de dollars américains, volumes en unités, prix en dollars américains |
|
Segments couverts |
Par produit (systèmes et services), réactif (réactifs d'imagerie optique préclinique, réactifs d'imagerie nucléaire préclinique, agents de contraste IRM préclinique, agents de contraste échographiques précliniques et agents de contraste CT préclinique), application (recherche et développement, découverte de médicaments, biodistribution, détection de cellules cancéreuses, biomarqueurs et autres), utilisateur final (organisme de recherche sous contrat, sociétés pharmaceutiques et biotechnologiques, instituts de recherche universitaires et gouvernementaux, centre de diagnostic et autres) |
|
Pays couverts |
Allemagne, France, Royaume-Uni, Italie, Espagne, Russie, Turquie, Belgique, Pays-Bas, Suisse et reste de l'Europe |
|
Acteurs du marché couverts |
PerkinElmer Inc., FUJIFILM Visualsonics, Inc., Bruker, Hologic, Inc., Zeiss International, Agilent Technologies, Inc., Hamamatsu Photonics KK, Vieworks Co., Ltd, LI-COR, Inc., Aspect Imaging Ltd., Berthold Technologies GmbH & Co.KG, MILabs BV, Trifoil Imaging, Mediso Ltd, IVIM Technology Inc., MR Solutions, AI4R, Photon et entre autres |
Définition du marché de l'imagerie préclinique en Europe
Preclinical imaging is the use of various imaging techniques and technologies to visualize and study biological processes, diseases, and drug responses in animal models before they are tested in humans. It involves the non-invasive imaging of animals, typically rodents, such as mice and rats, to gain insights into the underlying mechanisms of diseases and to evaluate the efficacy and safety of potential therapies.
Europe Preclinical Imaging Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Increasing Technology Advancement in the Field of Imaging
Preclinical imaging refers to the use of various imaging modalities to visualize and study the biological processes in animals before clinical trials. These systems help researchers to gain insight into disease mechanisms, evaluate potential drug candidates, and monitor treatment efficacy. Technology advancement in the field of imaging is playing a crucial role in driving the growth of the market.
Modern imaging technologies, such as high-resolution Magnetic Resonance Imaging (MRI), micro-Computed Tomography (micro-CT), and advanced ultrasound provide researchers with clearer and more detailed images of biological structures.
The integration of multimodal imaging systems is another advancement in the preclinical imaging market as these systems combine multiple imaging techniques, such as PET-CT or PET-MRI, to provide complementary information and enhance the accuracy of preclinical studies which allows researchers to investigate multiple aspects of a disease or treatment simultaneously, leading to more comprehensive and reliable results.
Furthermore, there have been significant improvements in image analysis and data processing algorithms. Advanced software tools and machine learning algorithms enable researchers to extract quantitative data from images, automate image processing tasks, and improve the accuracy and efficiency of data analysis. These advancements save time and enhance the reproducibility and reliability of preclinical studies.
High-resolution imaging techniques, multimodal imaging systems, and advanced image analysis algorithms are enhancing the capabilities of preclinical imaging and enabling researchers to gain deeper insights into disease mechanisms. Thus, the advancement in imaging technology is driving the growth of the market.
- Increasing Number of Investments and Funding in Research and Development
The increasing number of investments and funding in research and development (R&D) is a significant driver of the growth of the market. Organizations are allocating substantial resources to advance imaging technologies and support innovative research initiatives as the importance of preclinical imaging in drug discovery and development becomes more evident.
Investments and funding in R&D enable the development of novel preclinical imaging modalities and techniques. This financial support facilitates the improvement of imaging systems, software, and hardware, leading to enhanced image quality, resolution, and sensitivity. These advancements enable researchers to obtain more accurate and detailed information about biological processes, disease mechanisms, and treatment responses, driving the growth of the preclinical imaging market.
Furthermore, funding and investments in R&D also promote the translation of preclinical imaging research into clinical applications. Successful preclinical studies can attract further investment and partnerships, leading to the development of imaging techniques and technologies for human use. This expansion into clinical imaging applications further strengthens the preclinical imaging market.
Thus, the increasing number of investments and funding in research and development is a significant driver of the growth of the market.
Opportunity
- Increasing Adoption of Imaging Systems for Preclinical Purpose
The pharmaceutical and biotechnology industries are continually searching for novel drug candidates to address unmet medical needs. Preclinical imaging allows for a more comprehensive understanding of potential drug candidates by visualizing their effects on living organisms. This helps in identifying promising candidates and eliminating those with unfavorable characteristics earlier in the drug development process, saving time and resources. The shift toward personalized medicine requires a more thorough understanding of individual patients' conditions. Preclinical imaging can be used to assess disease heterogeneity and tailor treatment approaches, leading to more effective therapies.
Preclinical imaging techniques are generally non-invasive or minimally invasive, which is advantageous for both research animals and the accuracy of the data collected. This non-invasive nature enables longitudinal studies, reducing the need for sacrificing animals at multiple time points.
Hence, the increasing adoption of imaging systems for preclinical purposes may give an opportunity for the growth of the market in the forecast period.
Restraint / Challenge
- Stringent Regulatory Framework for Product Approval
Regulatory bodies around the world have established strict guidelines and requirements for the approval of preclinical imaging products, which can create barriers for companies in the market and is a significant restraining factor for market growth.
Regulatory agencies the European Medicines Agency (EMA) have implemented rigorous standards for product approval to ensure patient safety and the effectiveness of preclinical imaging products. These standards often include extensive preclinical testing, data submission, and adherence to Good Laboratory Practice (GLP) guidelines.
The regulatory process for preclinical imaging products is time-consuming and expensive. Companies conduct comprehensive studies to demonstrate the safety and efficacy of their products, which involves significant investment in research and development. In addition, the regulatory submission process requires extensive documentation, data analysis, and interaction with regulatory authorities, all of which add to the time and cost burden.
Furthermore, the stringent regulatory requirements may vary across different regions, creating additional challenges for companies operating in Europe markets. Companies must navigate the complex landscape of regulatory approvals in different countries, which can lead to delays in product launches and increased costs for compliance.
Thus, the stringent regulatory framework for product approval is a significant restraint for market growth.
Europe Preclinical Imaging Market Scope
Europe preclinical imaging market is segmented into four notable segments based on product, reagents, application, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Systems
- Services
On the basis of product, the Europe preclinical imaging market is segmented into systems and services.
Reagents
- Preclinical Optical Imaging Reagents
- Preclinical Nuclear Imaging Reagents
- Preclinical MRI Contrast Agents
- Preclinical Ultrasound Contrast Agents
- Preclinical CT Contrast Agents
On the basis of reagents, the market is segmented into preclinical optical imaging reagents, preclinical nuclear imaging reagents, preclinical MRI contrast agents, preclinical ultrasound contrast agents, and preclinical CT contrast agents.
Application
- Research and Development
- Drug Discovery
- Bio-Distribution
- Cancer Cell Detection
- Bio-Markers
- Others
On the basis of application, the market is segmented into research and development, drug discovery, bio-distribution, cancer cell detection, bio-markers, and others.
End User
- Contract Research Organization
- Pharmaceutical & Biotech Companies
- Academic & Government Research Institutes
- Diagnostics Center
- Others
On the basis of end user, the market is segmented into contract research organization, pharmaceutical & biotech companies, academic & government research institutes, diagnostics center, and others.
Regional Analysis/Insights: Europe Preclinical Imaging Market
Europe preclinical imaging market is analyzed and market size insights and trends are provided by country, product, reagents, application, and end user.
The countries covered in this market report are Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and rest of Europe.
Germany is expected to dominate the Europe region due to the growing demand for imaging devices and technological advancements.
La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques, l'analyse des cinq forces de Porter et les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour chaque pays. En outre, la présence et la disponibilité des marques d'Amérique du Nord et d'Amérique du Sud et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse de la concurrence et des parts de marché : marché européen de l'imagerie préclinique
Le paysage concurrentiel du marché européen de l'imagerie préclinique fournit des détails sur les concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les nouvelles initiatives du marché, la présence en Europe, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises par rapport au marché.
Certains des principaux acteurs du marché opérant sur le marché européen de l'imagerie préclinique sont PerkinElmer Inc., FUJIFILM Visualsonics, Inc, Bruker, Hologic, Inc, Zeiss International, Agilent Technologies, Inc., Hamamatsu Photonics KK, Vieworks Co., Ltd, LI-COR, Inc., Aspect Imaging Ltd., Berthold Technologies GmbH & Co.KG, MILabs BV, Trifoil Imaging, Mediso Ltd, IVIM Technology Inc., MR Solutions, AI4R, Photon et entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE PRECLINICAL IMAGING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 MARKET END USER COVERAGE GRID
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FIRCES
4.3 STRATEGIC INITIATIVES
4.4 CONCLUSION
5 REGULATORY FRAMEWORK
5.1 REGULATORY SCENARIO IN EUROPE
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING TECHNOLOGY ADVANCEMENT IN THE FIELD OF IMAGING
6.1.2 INCREASING NUMBER OF INVESTMENTS AND FUNDING IN RESEARCH AND DEVELOPMENT
6.1.3 INCREASING INCIDENCE OF CHRONIC DISEASES
6.2 RESTRAINTS
6.2.1 STRINGENT REGULATORY FRAMEWORK FOR PRODUCT APPROVAL
6.2.2 HIGH INSTALLATION AND OPERATIONAL COST OF PRECLINICAL IMAGING SYSTEMS
6.3 OPPORTUNITIES
6.3.1 INCREASING ADOPTION OF IMAGING SYSTEMS FOR PRECLINICAL PURPOSES
6.3.2 GROWING DEMAND FOR NON-INVASIVE SMALL-ANIMAL IMAGING METHODS
6.4 CHALLENGES
6.4.1 LACK OF SKILLED PROFESSIONALS FOR THE EFFECTIVE UTILIZATION OF PRECLINICAL IMAGING SYSTEMS
6.4.2 INTEGRATION OF IMAGING DEVICES WITH OTHER TECHNOLOGIES
7 EUROPE PRECLINICAL IMAGING MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 SYSTEMS
7.2.1 OPTICAL IMAGING SYSTEMS
7.2.1.1 BIOLUMINESCENCE/FLUORESCENCE IMAGING SYSTEMS
7.2.1.2 STANDALONE FLUORESCENCE IMAGING SYSTEMS
7.2.1.3 OPTICAL + X-RAY/OPTICAL + CT
7.2.2 PRECLINICAL NUCLEAR IMAGING SYSTEMS
7.2.2.1 MICRO-POSITRON EMISSION TOMOGRAPHY (PET) SYSTEMS
7.2.2.2 MICRO-SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SYSTEMS
7.2.2.3 TRIPRODUCT (SPECT/PET/CT) SYSTEMS
7.2.3 MICRO-MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS
7.2.4 MICRO-COMPUTED TOMOGRAPHY (CT) SYSTEMS
7.2.5 MICRO-ULTRASOUND SYSTEMS
7.2.6 PRECLINICAL PHOTOACOUSTIC IMAGING SYSTEMS
7.2.7 PRECLINICAL MAGNETIC PARTICLE IMAGING (MPI) SYSTEMS
7.2.8 MAGNETIC RESONANCE SPECTROSCOPY IMAGING (MRSI)
7.3 SERVICES
8 EUROPE PRECLINICAL IMAGING MARKET, BY REAGENTS
8.1 OVERVIEW
8.2 PRECLINICAL OPTICAL IMAGING REAGENTS
8.2.1 BIOLUMINESCENT IMAGING REAGENTS
8.2.2 FLUORESCENT IMAGING REAGENTS
8.3 PRECLINICAL NUCLEAR IMAGING REAGENTS
8.3.1 PRECLINICAL PET TRACERS
8.3.2 PRECLINICAL SPECT PROBES
8.4 PRECLINICAL MRI CONTRAST AGENTS
8.4.1 GADOLINIUM-BASED PRECLINICAL MRI CONTRAST AGENTS
8.4.2 MANGANESE-BASED PRECLINICAL MRI CONTRAST AGENTS
8.4.3 IRON-BASED PRECLINICAL MRI CONTRAST AGENTS
8.5 PRECLINICAL ULTRASOUND CONTRAST AGENTS
8.6 PRECLINICAL CT CONTRAST AGENTS
8.6.1 IODINE-BASED PRECLINICAL CT CONTRAST AGENTS
8.6.2 BARIUM-BASED PRECLINICAL CT CONTRAST AGENTS
8.6.3 GOLD NANOPARTICLES
8.6.4 GASTROGRAFIN-BASED PRECLINICAL CT CONTRAST AGENTS
9 EUROPE PRECLINICAL IMAGING MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 RESEARCH AND DEVELOPMENT
9.3 DRUG DISCOVERY
9.4 BIO-DISTRIBUTION
9.5 CANCER CELL DETECTION
9.6 BIO-MARKERS
9.7 OTHERS
10 EUROPE PRECLINICAL IMAGING MARKET, BY END USER
10.1 OVERVIEW
10.2 CONTRACT RESEARCH ORGANIZATION
10.3 PHARMACEUTICAL & BIOTECH COMPANIES
10.4 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES
10.5 DIAGNOSTICS CENTER
10.6 OTHERS
11 EUROPE PRECLINICAL IMAGING MARKET, BY REGION
11.1 EUROPE
11.1.1 GERMANY
11.1.2 FRANCE
11.1.3 U.K.
11.1.4 ITALY
11.1.5 SPAIN
11.1.6 RUSSIA
11.1.7 TURKEY
11.1.8 BELGIUM
11.1.9 NETHERLANDS
11.1.10 SWITZERLAND
11.1.11 REST OF EUROPE
12 EUROPE PRECLINICAL IMAGING MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 PERKINELMER INC.
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.2 FUJIFILM VISUALSONICS, INC
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 RECENT DEVELOPMENT
14.3 HOLOGIC, INC.
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENT
14.4 BRUKER
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 PRODUCT PORTFOLIO
14.4.4 RECENT DEVELOPMENT
14.5 ZEISS INTERNATIONAL
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENT
14.6 ADVANCED MOLECULAR VISION, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 PRODUCT PORTFOLIO
14.6.3 RECENT DEVELOPMENT
14.7 AGILENT TECHNOLOGIES, INC.
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 AI4R
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENT
14.9 BERTHOLD TECHNOLOGIES GMBH & CO.KG
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.1 HAMAMATSU PHOTONICS K.K.
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.11 IVIM TECHNOLOGY CORP.
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENT
14.12 LI-COR, INC.
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 MEDISO LTD.
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 MILABS B.V.
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENT
14.15 MR SOLUTIONS
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENT
14.16 PHOTON ETC
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 TRIFOIL IMAGING
14.17.1 COMPANY SNAPSHOT
14.17.2 PRODUCT PORTFOLIO
14.17.3 RECENT DEVELOPMENT
14.18 VIEWORKS CO., LTD.
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
Liste des tableaux
TABLE 1 EUROPE PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 2 EUROPE SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 3 EUROPE OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 4 EUROPE PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 5 EUROPE PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 6 EUROPE PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 7 EUROPE PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 8 EUROPE PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 9 EUROPE PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 10 EUROPE PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 11 EUROPE PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 12 EUROPE PRECLINICAL IMAGING MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 13 GERMANY PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 14 GERMANY SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 15 GERMANY SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 16 GERMANY SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 17 GERMANY OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 18 GERMANY OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 19 GERMANY OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 20 GERMANY PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 21 GERMANY PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 22 GERMANY PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 23 GERMANY PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 24 GERMANY PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 25 GERMANY PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 26 GERMANY PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 27 GERMANY PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 28 GERMANY PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 29 GERMANY PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 30 GERMANY PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 31 GERMANY PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 32 GERMANY PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 33 GERMANY PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 34 GERMANY PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 35 GERMANY PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 36 GERMANY PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 37 GERMANY PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 38 GERMANY PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 39 GERMANY PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 40 FRANCE PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 41 FRANCE SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 42 FRANCE SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 43 FRANCE SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 44 FRANCE OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 45 FRANCE OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 46 FRANCE OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 47 FRANCE PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 48 FRANCE PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 49 FRANCE PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 50 FRANCE PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 51 FRANCE PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 52 FRANCE PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 53 FRANCE PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 54 FRANCE PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 55 FRANCE PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 56 FRANCE PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 57 FRANCE PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 58 FRANCE PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 59 FRANCE PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 60 FRANCE PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 61 FRANCE PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 62 FRANCE PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 63 FRANCE PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 64 FRANCE PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 65 FRANCE PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 66 FRANCE PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 67 U.K. PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 68 U.K. SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 69 U.K. SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 70 U.K. SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 71 U.K. OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 72 U.K. OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 73 U.K. OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 74 U.K. PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 75 U.K. PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 76 U.K. PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 77 U.K. PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 78 U.K. PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 79 U.K. PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 80 U.K. PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 81 U.K. PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 82 U.K. PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 83 U.K. PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 84 U.K. PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 85 U.K. PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 86 U.K. PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 87 U.K. PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 88 U.K. PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 89 U.K. PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 90 U.K. PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 91 U.K. PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 92 U.K. PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 93 U.K. PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 94 ITALY PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 95 ITALY SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 96 ITALY SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 97 ITALY SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 98 ITALY OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 99 ITALY OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 100 ITALY OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 101 ITALY PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 102 ITALY PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 103 ITALY PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 104 ITALY PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 105 ITALY PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 106 ITALY PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 107 ITALY PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 108 ITALY PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 109 ITALY PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 110 ITALY PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 111 ITALY PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 112 ITALY PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 113 ITALY PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 114 ITALY PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 115 ITALY PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 116 ITALY PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 117 ITALY PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 118 ITALY PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 119 ITALY PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 120 ITALY PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 121 SPAIN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 122 SPAIN SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 123 SPAIN SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 124 SPAIN SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 125 SPAIN OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 126 SPAIN OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 127 SPAIN OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 128 SPAIN PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 129 SPAIN PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 130 SPAIN PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 131 SPAIN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 132 SPAIN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 133 SPAIN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 134 SPAIN PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 135 SPAIN PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 136 SPAIN PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 137 SPAIN PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 138 SPAIN PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 139 SPAIN PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 140 SPAIN PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 141 SPAIN PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 142 SPAIN PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 143 SPAIN PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 144 SPAIN PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 145 SPAIN PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 146 SPAIN PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 147 SPAIN PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 148 RUSSIA PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 149 RUSSIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 150 RUSSIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 151 RUSSIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 152 RUSSIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 153 RUSSIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 154 RUSSIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 155 RUSSIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 156 RUSSIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 157 RUSSIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 158 RUSSIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 159 RUSSIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 160 RUSSIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 161 RUSSIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 162 RUSSIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 163 RUSSIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 164 RUSSIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 165 RUSSIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 166 RUSSIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 167 RUSSIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 168 RUSSIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 169 RUSSIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 170 RUSSIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 171 RUSSIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 172 RUSSIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 173 RUSSIA PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 174 RUSSIA PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 175 TURKEY PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 176 TURKEY SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 177 TURKEY SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 178 TURKEY SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 179 TURKEY OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 180 TURKEY OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 181 TURKEY OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 182 TURKEY PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 183 TURKEY PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 184 TURKEY PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 185 TURKEY PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 186 TURKEY PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 187 TURKEY PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 188 TURKEY PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 189 TURKEY PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 190 TURKEY PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 191 TURKEY PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 192 TURKEY PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 193 TURKEY PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 194 TURKEY PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 195 TURKEY PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 196 TURKEY PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 197 TURKEY PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 198 TURKEY PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 199 TURKEY PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 200 TURKEY PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 201 TURKEY PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 202 BELGIUM PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 203 BELGIUM SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 204 BELGIUM SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 205 BELGIUM SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 206 BELGIUM OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 207 BELGIUM OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 208 BELGIUM OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 209 BELGIUM PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 210 BELGIUM PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 211 BELGIUM PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 212 BELGIUM PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 213 BELGIUM PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 214 BELGIUM PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 215 BELGIUM PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 216 BELGIUM PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 217 BELGIUM PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 218 BELGIUM PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 219 BELGIUM PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 220 BELGIUM PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 221 BELGIUM PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 222 BELGIUM PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 223 BELGIUM PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 224 BELGIUM PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 225 BELGIUM PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 226 BELGIUM PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 227 BELGIUM PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 228 BELGIUM PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 229 NETHERLANDS PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 230 NETHERLANDS SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 231 NETHERLANDS SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 232 NETHERLANDS SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 233 NETHERLANDS OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 234 NETHERLANDS OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 235 NETHERLANDS OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 236 NETHERLANDS PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 237 NETHERLANDS PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 238 NETHERLANDS PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 239 NETHERLANDS PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 240 NETHERLANDS PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 241 NETHERLANDS PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 242 NETHERLANDS PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 243 NETHERLANDS PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 244 NETHERLANDS PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 245 NETHERLANDS PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 246 NETHERLANDS PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 247 NETHERLANDS PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 248 NETHERLANDS PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 249 NETHERLANDS PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 250 NETHERLANDS PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 251 NETHERLANDS PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 252 NETHERLANDS PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 253 NETHERLANDS PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 254 NETHERLANDS PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 255 NETHERLANDS PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 256 SWITZERLAND PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 257 SWITZERLAND SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 258 SWITZERLAND SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 259 SWITZERLAND SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 260 SWITZERLAND OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 261 SWITZERLAND OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 262 SWITZERLAND OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 263 SWITZERLAND PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 264 SWITZERLAND PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 265 SWITZERLAND PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 266 SWITZERLAND PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 267 SWITZERLAND PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 268 SWITZERLAND PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 269 SWITZERLAND PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 270 SWITZERLAND PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 271 SWITZERLAND PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 272 SWITZERLAND PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 273 SWITZERLAND PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 274 SWITZERLAND PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 275 SWITZERLAND PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 276 SWITZERLAND PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 277 SWITZERLAND PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 278 SWITZERLAND PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 279 SWITZERLAND PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 280 SWITZERLAND PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 281 SWITZERLAND PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 282 SWITZERLAND PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 283 REST OF EUROPE PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
Liste des figures
FIGURE 1 EUROPE PRECLINICAL IMAGING MARKET: SEGMENTATION
FIGURE 2 EUROPE PRECLINICAL IMAGING MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE PRECLINICAL IMAGING MARKET: DROC ANALYSIS
FIGURE 4 EUROPE PRECLINICAL IMAGING MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 EUROPE PRECLINICAL IMAGING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE PRECLINICAL IMAGING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE PRECLINICAL IMAGING MARKET: MARKET END USERS COVERAGE GRID
FIGURE 8 EUROPE PRECLINICAL IMAGING MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE PRECLINICAL IMAGING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE PRECLINICAL IMAGING MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE OF CHRONIC DISORDER AND ADVANCEMENTS IN IMAGING TECHNIQUES ARE EXPECTED TO DRIVE THE GROWTH OF THE EUROPE PRECLINICAL IMAGING MARKET FROM 2023 TO 2030
FIGURE 12 SYSTEMS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE PRECLINICAL MARKET IN 2023 AND 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE PRECLINICAL IMAGING MARKET
FIGURE 14 EUROPE PRECLINICAL IMAGING MARKET: BY PRODUCT, 2022
FIGURE 15 EUROPE PRECLINICAL IMAGING MARKET: BY PRODUCT, 2023-2030 (USD MILLION)
FIGURE 16 EUROPE PRECLINICAL IMAGING MARKET: BY PRODUCT, CAGR (2023-2030)
FIGURE 17 EUROPE PRECLINICAL IMAGING MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 18 EUROPE PRECLINICAL IMAGING MARKET: BY REAGENTS, 2022
FIGURE 19 EUROPE PRECLINICAL IMAGING MARKET: BY REAGENTS, 2023-2030 (USD THOUSANDS)
FIGURE 20 EUROPE PRECLINICAL IMAGING MARKET: BY REAGENTS, CAGR (2023-2030)
FIGURE 21 EUROPE PRECLINICAL IMAGING MARKET: BY REAGENTS, LIFELINE CURVE
FIGURE 22 EUROPE PRECLINICAL IMAGING MARKET: BY APPLICATION, 2022
FIGURE 23 EUROPE PRECLINICAL IMAGING MARKET: BY APPLICATION, 2023-2030 (USD THOUSANDS)
FIGURE 24 EUROPE PRECLINICAL IMAGING MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 25 EUROPE PRECLINICAL IMAGING MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 26 EUROPE PRECLINICAL IMAGING MARKET: BY END USER, 2022
FIGURE 27 EUROPE PRECLINICAL IMAGING MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 EUROPE PRECLINICAL IMAGING MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 EUROPE PRECLINICAL IMAGING MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 EUROPE PRECLINICAL IMAGING MARKET: SNAPSHOT (2022)
FIGURE 31 EUROPE PRECLINICAL IMAGING MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
